Patents Issued in March 25, 2021
-
Publication number: 20210085603Abstract: This invention relates to a composition for ophthalmic delivery of a therapeutic agent, the composition comprising an oil-in-water (o/w) microemulsion comprising a fatty acid, or fatty acid ester, as the oil phase; an aqueous phase; a surfactant; and a co-surfactant, and wherein the composition further comprise a suspension of therapeutic agent-loaded nanoparticles. Use of the composition for the treatment or prevention of an eye disorder, a method of treatment or prevention of an eye disorder and an eye drop dispenser are also provided.Type: ApplicationFiled: December 21, 2018Publication date: March 25, 2021Applicant: Waterford Institute of TechnologyInventors: Gautam BEHL, Sangeeta KUMARI, Niall O'REILLY, Orla O'DONOVAN, Peter MCLOUGHLIN, David KENT, Laurence FITZHENRY
-
Publication number: 20210085604Abstract: An object of the present invention is to provide a compound or a salt thereof constituting lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids, and to provide lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids. According to an aspect of the present invention, a compound represented by Formula (1) or a salt thereof is provided.Type: ApplicationFiled: December 4, 2020Publication date: March 25, 2021Applicant: FUJIFILM CorporationInventors: Shintaro TANABE, Masahiko YAMAMOTO, Kimihiko SATO, Motomasa TAKAHASHI, Kazuhiro TSUNA, Yasutaka TASAKI, Taisuki ENDO, Issei DOI, Hirofumi FUKUNAGA
-
Publication number: 20210085605Abstract: Provided is a pharmaceutical composition comprising a collection of particles, wherein the particles comprise a drug and an ion exchange resin, wherein the ion exchange resin comprises 9% to 30% polymerized units of one or more multifunctional vinyl monomer, by weight based on the dry weight of the ion exchange resin.Type: ApplicationFiled: December 19, 2018Publication date: March 25, 2021Inventors: Elizabeth Tocce, Amie Gehris, Silvia Szep
-
Publication number: 20210085606Abstract: The disclosure provides a use of hydrogel composition for alleviating degenerative joint and tendon tear. The hydrogel composition includes 100 parts by weight of therapeutic agent and 120-380 parts by weight of biodegradable copolymer, wherein the therapeutic agent comprises platelet-rich plasma (PRP), doxorubicin, transforming growth factor, bovine serum albumin, or a combination thereof. The biodegradable copolymer has a structure of Formula (I) or Formula (II): wherein A is a hydrophilic polyethylene glycol polymer; B is a hydrophobic polyester polymer; BOX is a bifunctional group monomer of 2, 2?-bis(2-oxazoline) used for coupling the blocks A-B or B-A-B; and n is 0 or an integer greater than 0.Type: ApplicationFiled: December 7, 2020Publication date: March 25, 2021Applicant: Industrial Technology Research InstituteInventors: Hsin-Hsin SHEN, Wen-Shiang CHEN, Chueh-Hung WU, Ming-Kuan SUN, Yu-Chi WANG, Sen-Lu CHEN, Wei-Lin YU, Lih-Tao HSU, Shih-Ping LIN
-
Publication number: 20210085607Abstract: The present invention is in the field of manufacturing drug-loaded microparticles, and specifically provides processes for producing approximately homogenously sized drug loaded microparticles with high drug loading and reproducible drug release profiles, and which may be provided in a significantly reduced time period.Type: ApplicationFiled: October 22, 2020Publication date: March 25, 2021Applicant: Graybug Vision, Inc.Inventors: Daniel Saragnese, Ming Yang, Yun Yu, Toni-Rose Guiriba, David McKenzie
-
Publication number: 20210085608Abstract: A composition of, method for producing, and use of an amorphous lyophilized Phenobarbital Sodium having high purity are presented. The amorphous lyophilized Phenobarbital Sodium is storage-stable being essentially void of impurities (e.g., phenylethylacetylurea (PEAU), 2-ethyl-2-phenylmalonamide (2EPMM), and/or alpha-phenylbutyrylguanidine (PBG)) upon reconstitution in water.Type: ApplicationFiled: September 18, 2020Publication date: March 25, 2021Applicant: Nivagen Pharmaceuticals, Inc.Inventors: Bala Tripura Sundari Chodavarapu, Thirupathi Mangali, Jay Shukla, Anand Shukla, Dasaradhi Lakkaraju
-
Publication number: 20210085609Abstract: The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.Type: ApplicationFiled: December 2, 2020Publication date: March 25, 2021Applicant: XSPRAY PHARMA ABInventors: Per ANDERSSON, Thomas MEIJER, Victor SÖDERBERG
-
Publication number: 20210085610Abstract: The present invention relates to a solid unit dosage form for oral administration (tablet or granules) containing a solid dispersion of valsartan and sacubitril in a polymeric matrix. The solid dispersion is prepared by hot-melt extrusion and may contain the active ingredients preferably in a non-crystalline state. LCZ696, (pseudo)polymorphic forms thereof as well as the individual drugs, e.g. valsartan disodium and sacubitril monosodium, may be subjected to the hot-melt extrusion process.Type: ApplicationFiled: March 29, 2018Publication date: March 25, 2021Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)Inventors: Bala Ramesha Chary RALLABANDI, Vamshi Ramana PRATHAP, Rajesh Krishna Mohan GOLLAPUDI, Hendrik SCHLEHAHN, Dieter RUCHATZ
-
Publication number: 20210085611Abstract: A pharmaceutical formulation has (S)-[2-chloro-4-fluoro-5-(7-tnorpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 28, 2018Publication date: March 25, 2021Applicant: Merck Patent GmbHInventors: Simon GEISSLER, Martina Jeschke, Patrizia Boniforte, Markus Weigandt
-
Publication number: 20210085612Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein “Ra” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.Type: ApplicationFiled: December 3, 2020Publication date: March 25, 2021Inventors: Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, JR., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
-
Publication number: 20210085613Abstract: This disclosure is directed to ibudilast higher dosage oral formulations, such as tablet or capsule formulations, and the corresponding methods of treatment.Type: ApplicationFiled: September 21, 2020Publication date: March 25, 2021Applicant: MediciNova, Inc.Inventors: Kazuko Matsuda, Federico Carlos Aréjola Gaeta
-
Publication number: 20210085614Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.Type: ApplicationFiled: December 4, 2020Publication date: March 25, 2021Applicant: Acorda Therapeutics, Inc.Inventors: Joseph E. Cobb, Jr., Thomas B. Gold, Rohini D'Souza, Susan L. Way
-
Publication number: 20210085615Abstract: The present invention provides a biomolecular composite which is a ghost cell which has been emptied of all or substantially all of the cytosolic contents of the cell including the nucleus and nuclear contents, preferably further having been fused with exogenous amphipathic molecules, wherein said composite has a hydrodynamic diameter of less than 6 ?m. The biomolecular composite may contain a cargo molecule and be capable of targeting a cell or tissue. Also provided are methods of preparing ghost cells, methods of preparing biomolecular composites and methods for their use.Type: ApplicationFiled: July 27, 2018Publication date: March 25, 2021Applicant: National University of SingaporeInventors: Wei Jiang Goh, Giorgia Pastorin, Shui Zou
-
Publication number: 20210085616Abstract: In one aspect, the present disclosure provides microparticles that are configured to release a first drug over a first time period and to release a second drug over a second time period, wherein a lag period of substantially no drug release occurs between the first and second time periods. In other aspects, the present disclosure pertains to the use of such microparticles in delivery systems and methods of treatment. In another aspect, the present disclosure pertains to drug delivery systems that comprising a folded inflatable drug delivery balloon that comprises folds and microparticles positioned within the folds.Type: ApplicationFiled: December 2, 2020Publication date: March 25, 2021Inventors: Javier Palomar-Moreno, Michelle Hannon, Phillip Bannister
-
Publication number: 20210085617Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.Type: ApplicationFiled: December 3, 2020Publication date: March 25, 2021Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Randal A. Seburg, Manuel A. Vega Zepeda
-
Publication number: 20210085618Abstract: This invention relates to a Nanostructured Lipid Carrier (NLC) particle comprising a therapeutic agent encapsulated therein for ocular delivery of the therapeutic agent, wherein the Nanostructured Lipid Carrier comprises: (i) a solid outer shell comprising a solid lipid, and (ii) a liquid core comprising a liquid lipid; and wherein the core comprises the therapeutic agent. Compositions of the NLC particles, use of the NLC particles, methods of treatment or prevention of an eye disorder and an eye drop dispenser are also provided.Type: ApplicationFiled: December 21, 2018Publication date: March 25, 2021Applicant: Waterford Institute Of TechnologyInventors: Gautam BEHL, Sangeeta KUMARI, Niall O'REILLY, Orla O'DONOVAN, Peter MCLOUGHLIN, David KENT, Laurence FITZHENRY, Elke BEHAEGHEL
-
Publication number: 20210085619Abstract: Pharmaceutical formulations (nanococktails) include two or more nanoparticulate delivery vehicles each including an active agent. The nanococktails can be formulated at any ratio of active agents by changing the ratio of nanoparticulate delivery vehicles in the nanococktail. The nanoparticulate delivery vehicles can have matched surface potential to prevent aggregation. The nanoparticulate delivery vehicles of the combined formulation are designed to provide each active agent with desired, preferably overlapping therapeutic windows and a specifically selected pharmacokinetic and pharmacodynamic profile when the nanococktail is administered to a subject. Each of the nanoparticulate delivery vehicles can be designed to enhance solubility, duration of action, targeting, stability, and to program release while preventing degradation of an active agent and preventing side effects, toxicity, and tolerability issues in a subject.Type: ApplicationFiled: September 23, 2020Publication date: March 25, 2021Inventors: Paige BALDWIN, Srinivas SRIDHAR, Bijay SINGH
-
Publication number: 20210085620Abstract: This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of a pathogenic mycobacterial infection.Type: ApplicationFiled: July 13, 2018Publication date: March 25, 2021Inventors: Koenraad Jozef Lodewijk Marcel Andries, Marisieiia Bernini, Esther Dina Guido Basstanie
-
Publication number: 20210085621Abstract: The present applications provides methods of treating pulmonary hypertension (e.g., severe form of pulmonary arterial hypertension, e.g., WHO functional class III or IV pulmonary arterial hypertension) in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (e.g., rapamycin or a derivative thereof, e.g., rapamycin) and a earner protein (e.g., an albumin).Type: ApplicationFiled: November 19, 2020Publication date: March 25, 2021Inventors: Neil P. DESAI, Shihe HOU
-
Publication number: 20210085622Abstract: A pharmaceutical active-containing transmucosal delivery device comprises a polymer film comprising a polymer matrix, wherein the film has a pH in the range of about 4 to about 9, and a pharmaceutical active composition disposed on a surface of the polymer film. The composition comprises at least one pharmaceutical active ingredient in the form of particles, and wherein the particles have an average particle size of about 100 nm to about 5 microns, an anti-crystallization agent, and a pH adjusting agent, wherein the concentration of the pharmaceutical active ingredient is at least 20% w/w relative to the total weight of the pharmaceutical active composition. The delivery device exhibits a residence time in the mouth of a subject ranging from about 5 minutes to about 30 minutes and is substantially mucoadhesive to a mucosa surface when placed sublingually under the tongue or placed buccally at the inner lining of the cheek.Type: ApplicationFiled: February 22, 2019Publication date: March 25, 2021Inventors: Samarth VASISHT, Niraj VASISHT
-
Publication number: 20210085623Abstract: The invention relates to transdermal drug delivery patches, in particular the provision of excipients that augment the drug release properties of the patches. The excipients typically involve a mixture of glycols, alkoxy alcohol and sulfoxides depending on the particular drug to be delivered.Type: ApplicationFiled: April 30, 2018Publication date: March 25, 2021Applicant: Medherant LimitedInventor: David Haddleton
-
Publication number: 20210085624Abstract: Compositions and methods can use a combination of an autophagy inducer, such as spermidine, and high protein for induction of autophagy in an individual in need thereof. Preferably, a formulation containing a combination of an autophagy inducer and high protein is administered to the individual in an amount effective to induce autophagy, for example in muscle. The formulation can concomitantly promote protein synthesis and removal of damaged cellular materials. The recipient of administration can be a critically ill patient, for example a patient in the Intensive Care Unit (ICU), and/or an ageing patient, for example an elderly individual or an individual with sarcopenia.Type: ApplicationFiled: December 19, 2018Publication date: March 25, 2021Inventors: Gabriele Civiletto, Bernard Cuenoud, Jerome Feige, Philipp Gut
-
Publication number: 20210085625Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.Type: ApplicationFiled: December 4, 2020Publication date: March 25, 2021Inventors: John MCKEARN, Jeremy BLITZER
-
Publication number: 20210085626Abstract: Described herein are compounds of Formula I, or pharmaceutically acceptable salts thereof, or combinations thereof, as well as uses thereof. Such uses include promoting tissue self-repair or tissue regeneration of an organ, stimulating the generation of tissue growth, modulating (e.g., increasing) the level of a tissue-repair marker, treating physical injury in an organ, tissue or cell, promoting wound healing, as well as anti-aging applications. Corresponding compositions, methods, kits, and uses are also described. Formula I wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F of OH; R2 is H, F, OH, C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH, or CH2Ph; R4 is H, F or OH; Q is 1) (CH2), C(O)OH wherein m is 1 or 2 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH or 6) C(O)—C(O)OH.Type: ApplicationFiled: December 3, 2020Publication date: March 25, 2021Inventors: Lyne GAGNON, Pierre LAURIN
-
Publication number: 20210085627Abstract: The present disclosure provides compositions comprising 18-HEPE, 12-HEPE, and/or a derivative thereof and methods of using same to treat a variety of diseases and disorders.Type: ApplicationFiled: September 25, 2019Publication date: March 25, 2021Inventors: David Coughlan, Moayed Hamza
-
Publication number: 20210085628Abstract: The present disclosure provides compositions comprising 15-HEPE and methods of using same for treating and/or preventing cancer and neurological diseases in a subject in need thereof.Type: ApplicationFiled: June 5, 2020Publication date: March 25, 2021Inventors: John Climax, David Coughlan
-
Publication number: 20210085629Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing sdLDL oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: ApplicationFiled: October 19, 2020Publication date: March 25, 2021Inventor: Richard Preston Mason
-
Publication number: 20210085630Abstract: A pharmaceutical composition includes chlorogenic acid and coumaroylquinic acid. It can be used for preparing a reversing agent for tumor multi-drug resistance and a PD-1/PD-L1 inhibitor. The combined use of chlorogenic acid and coumaroylquinic acid exhibits a synergistic effect, effectuating a good reversing effect on the drug resistance of a tumor cell strain that produces multi-drug resistance for chemotherapeutic drugs and immunotherapeutic drugs, which may effectively inhibit PD-1/PD-L1 expression in drug-resistant B16 melanoma and drug-resistant Lewis lung cancer mice transplantation tumor tissue, and may effectively proliferate CD4+T and CD8+T cells in drug-resistant B16 melanoma mice and Lewis lung cancer mice.Type: ApplicationFiled: March 12, 2019Publication date: March 25, 2021Inventors: Jie ZHANG, Xiaoguang CHEN, Huarong YANG, Wang HUANG
-
Publication number: 20210085631Abstract: Solid oral dosage forms, especially tablets, of a pharmaceutical composition comprising a supramolecular complex can be formed from a direct compression process or a compaction process such as roller compaction. Such solid oral dosage forms feature an immediate release profile that allows for fast release of the therapeutic agent. A particularly useful supramolecular complex is trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3?-methyl-2?-(pentanoyl{2?-(tetrazol-5-ylate)biphenyl-4?-ylmethyl}amino)butyrate]hemipentahydrate.Type: ApplicationFiled: December 2, 2020Publication date: March 25, 2021Inventors: Suliman AL-FAYOUMI, Jiahui HU, Natrajan KUMARAPERUMAL, Alan E. ROYCE, Colleen RUEGGER, Erika A. ZANNOU
-
COMPOSITIONS COMPRISING A FATTY ACID OIL MIXTURE AND A FREE FATTY ACID, AND METHODS AND USES THEREOF
Publication number: 20210085632Abstract: Compositions comprising a fatty acid oil mixture and at least one free fatty acid, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS) or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. Preferred fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a form chosen from ethyl ester and triglyceride.Type: ApplicationFiled: March 24, 2020Publication date: March 25, 2021Inventors: Svein Olaf HUSTVEDT, Preben Houlberg OLESEN, Gunnar BERGE, Anette MULLERTZ -
Publication number: 20210085633Abstract: The purpose of the present invention is to provide a rivastigmine-containing transdermal absorption preparation having high adhesion to the skin and capable of continuously administering rivastigmine over a long period of time. A transdermal absorption preparation has rivastigmine, a rubber polymer, a tackifier resin, and a polymer compound having a nitrogen-containing group.Type: ApplicationFiled: July 12, 2018Publication date: March 25, 2021Applicant: TEIKOKU SEIYAKU CO., LTD.Inventors: Satoshi KAWAKAMI, Manabu SOGABE, Taiki SHIBATA
-
Publication number: 20210085634Abstract: The present disclosure provides methods of identifying patients who have partial or total resistance to HIF-2 inhibitors or who develop partial or total resistance to HIF-2 inhibitors after treatment and providing suitable treatment to these patients.Type: ApplicationFiled: September 23, 2020Publication date: March 25, 2021Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: James B. BRUGAROLAS, Haley HILL, Tao WANG
-
Publication number: 20210085635Abstract: The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising (i) levodopa in an amount ranging from 50 mg to 300 mg, (ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and (iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight.Type: ApplicationFiled: October 7, 2020Publication date: March 25, 2021Inventors: Juha ROURU, Mikko KUOPPAMÄKI, Juha ELLMEN, Pekka MÄNNISTÖ
-
Publication number: 20210085636Abstract: A combination of the present invention is an effective therapy for glaucoma, in particular a combination of 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate and a ?-blocker, is useful as an agent for treating glaucoma since the combination enhances intraocular pressure lowering action compared to a single administration of each drug and has an effect of maintaining intraocular pressure lowering action.Type: ApplicationFiled: December 20, 2018Publication date: March 25, 2021Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shinsaku YAMANE, Satoshi NAKAYAMA, Kazufumi NAGAI, Kazumi MORIYUKI, Tomohiro KARAKAWA
-
Publication number: 20210085637Abstract: A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.Type: ApplicationFiled: July 27, 2017Publication date: March 25, 2021Inventor: Christopher U. Missling
-
Publication number: 20210085638Abstract: The present invention administers a cannabinoid medication to a patient followed by observing one or more physiological responses in the patient during a first period of time when treating a medical condition. The cannabinoid medication may include one or more specific types of cannabinoids at a dosage level or may include a plurality of discrete formulations where each formulation includes masses of specific cannabinoids that may be used for treating one or more ailments.Type: ApplicationFiled: October 5, 2020Publication date: March 25, 2021Inventor: Andrew Hospodor
-
Publication number: 20210085639Abstract: The present invention provides a method of preventing, reducing or attenuating acute kidney injury in a subject at risk of experiencing a transient increase in kidney ischemia or hypoxia, comprising administering to the subject an effective amount of an agent that binds to and neutralizes endogenous ouabain (EO).Type: ApplicationFiled: December 4, 2020Publication date: March 25, 2021Inventors: Mordecai P. Blaustein, John Hamlyn, Stephen Gottlieb, Ling Chen
-
Publication number: 20210085640Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating a cancer marker or for treating cancer.Type: ApplicationFiled: December 3, 2020Publication date: March 25, 2021Inventors: Steven John TAYLOR, Leonard BUCKBINDER, John Robert PROUDFOOT, Mi-Jeong KIM, Timothy F. BRIGGS, Ferdinand Edward MASSARI, Spencer Cory PECK, Koji YASUDA, Amir MOAREFI, David Arthur BERRY, John Patrick CASEY, JR.
-
Publication number: 20210085641Abstract: Tannin-containing compositions and methods of using same to enhance or maintain immune function during simplified nutrition feeding. Pharmaceutical compositions, including enteral nutrition compositions, are provided. The compositions comprise such tannins as proanthocyanidins and/or hydrolysable tannins. Administering the tannins to the gastrointestinal tract of a subject receiving simplified nutrition, such as with enteral nutrition therapy or parenteral nutrition therapy, attenuates or prevents deleterious effects on the gastrointestinal immune system that would otherwise occur with the simplified nutrition.Type: ApplicationFiled: December 4, 2020Publication date: March 25, 2021Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Jess Dreher Reed, Dhanansayan Shanmuganayagam, Christian Gerald Krueger, Kenneth Allan Kudsk, Joseph Francis Pierre, Aaron F. Heneghan, Rodrigo P. Feliciano
-
Publication number: 20210085642Abstract: Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.Type: ApplicationFiled: October 1, 2020Publication date: March 25, 2021Inventors: Anurag Singh, Davide D'Amico, Penelope Andreux, William Blanco-Bose, Christopher L. Rinsch
-
Publication number: 20210085643Abstract: The present invention relates to a method for treating a subject suffering from a liver disease comprising a step of administering said subject with a therapeutically effective amount of an inhibitor of the endoribonuclease activity of IRE1?. Inventors have shown that in livers of tunicamycin-treated BI-1?/? mice aIRE1?-dependent NLRP3 inflammasome activation, an hepatocyte death, a fibrosis and a dysregulated lipid homeostasis that led to liver failure within a week. To test whether the pharmacological inhibition of IRE1? endoribonuclease activity would block the transition to NASH, mice were injected with the small molecule STF-083010 twice a week for 2 weeks towards the end of a 3-month HFD. In BI-1?/? mice, STF-083010 treatment effectively counteracted IRE1? endoribonuclease activity, improving glucose tolerance and rescuing from NASH.Type: ApplicationFiled: February 15, 2019Publication date: March 25, 2021Inventors: Beatrice BAILLY-MAITRE RE, Philippe GUAL, Albert TRAN
-
Publication number: 20210085644Abstract: The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.Type: ApplicationFiled: July 2, 2020Publication date: March 25, 2021Inventors: Mukul R. Jain, Deven V. Parmar, Suresh Giri, Binu Philip, Pankaj Patel
-
Publication number: 20210085645Abstract: Provided herein are maternal neonatal pheromonal agents capable of reducing aggression and improving feeding behavior in a pig. Compositions comprising the pheromonal agents and methods of using the agents to reduce aggression and improve feeding behavior and weight gain in the pig are also provided.Type: ApplicationFiled: September 21, 2020Publication date: March 25, 2021Applicant: TEXAS TECH UNIVERSITY SYSTEMInventor: John J. McGlone
-
Publication number: 20210085646Abstract: The present invention relates to an orally disintegrated tablet and a method for producing same, the tablet containing a carbamate compound of chemical formula 1, an isomer thereof, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof, as an active ingredient.Type: ApplicationFiled: December 14, 2017Publication date: March 25, 2021Applicant: SK BIOPHARMACEUTICALS CO., LTD.Inventors: Myoung Ki BAEK, So Young CHOI, Ji Hye LEE
-
Publication number: 20210085647Abstract: IT-139, sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.Type: ApplicationFiled: September 29, 2020Publication date: March 25, 2021Inventors: Suzanne BAKEWELL, Jyothi SETHURAMAN
-
Publication number: 20210085648Abstract: Described herein are novel ?- and ?-propargyl carboxylic acids and esters. The novel compositions are antagonists of CSE and may be used to modulate of the activity of the carotid body, therefore providing therapeutic benefits for sleep-related breathing disorders and related conditions.Type: ApplicationFiled: May 6, 2020Publication date: March 25, 2021Inventors: Michael J. KATES, Nanduri R. PRABHAKAR, David L. MCCORMICK, Miguel MUZZIO
-
Publication number: 20210085649Abstract: The invention provides methods and agents that modulate RelA activity. These methods and modulators of RelA activity can be used to treat cancer progression of basal-like breast cancer, such as triple-negative breast cancer.Type: ApplicationFiled: December 1, 2020Publication date: March 25, 2021Applicant: Cedars-Sinai Medical CenterInventors: Ramachandran MURALI, Hirotaka KANZAKI
-
Publication number: 20210085650Abstract: Certain embodiments are directed to methods and compositions for treating cancer, specifically colorectal cancer by administering an aldose reductase inhibitor and an immune checkpoint inhibitor to a subject in need thereof. Certain embodiments are directed to methods of treating a subject having cancer comprising, administering (i) a composition comprising an aldose reductase specific inhibitor and (ii) a composition comprising an immune checkpoint inhibitor to the subject having melanoma, head and neck, or colorectal cancer.Type: ApplicationFiled: February 22, 2019Publication date: March 25, 2021Inventors: Satish K. SRIVASTAVA, Kota V. RAMANA, Ashish SAXENA
-
Publication number: 20210085651Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: ApplicationFiled: December 7, 2020Publication date: March 25, 2021Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Tasir Shamsul Haque, Louis J. Lombardo, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar, Trevor C. Sherwood, Shoshana L. Posy, Ramesh Kumar Sistla, Subramanya Hegde, Anupama Kandhi Ramachandra Reddy
-
Publication number: 20210085652Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.Type: ApplicationFiled: November 11, 2020Publication date: March 25, 2021Inventors: Ryu Oshima, Gary Gordon